Biotech Breakouts, Amphitheater Ambitions, and Chips on the Move
DENVER, Colo., Oct 16, 2025 (247marketnews.com)- Biotech breakthroughs, next-gen entertainment plays, and semiconductor momentum are driving standout action. Here’s your power hour pulse check:
Praxis Precision Medicines (NASDAQ:PRAX) is the top biotech mover of the day, soaring after the company reported positive topline results from two pivotal Phase 3 trials of ulixacaltamide, its investigational drug for essential tremor (ET).
- Study 1: Patients saw a 4.3-point improvement in mADL11 at Week 8 (p<0.0001).
- Study 2: 55% of treated patients maintained response, versus 33% on placebo (p=0.0369).
- No serious adverse events tied to the drug were reported.
Praxis has already submitted a pre-NDA meeting request with the FDA, aiming for a 2026 submission. CEO Marcio Souza emphasized the unmet need, while Dr. Salima Brillman said the results present “a real opportunity to help people regain their independence.”
With over 200,000 study volunteers and strong efficacy/safety data, PRAX is positioning ulixacaltamide as a potential first-in-class treatment in the CNS space.
VENU (NYSE:VENU) is getting a standing ovation on Wall Street after unveiling bold new designs for its Sunset Amphitheaters in McKinney, TX and Broken Arrow, OK.
- $23M in Luxe FireSuite sales secured in just 60 days
- Analyst coverage cites a $22.30 Cenorium price target
- Cultural ties include Dierks Bentley and Rolling Stone Culture Council
These venues offer more than music, with heated canopies, year-round programming, and a luxe customer focus, VENU is shifting its image from infrastructure builder to aspirational lifestyle brand. The message is clear: this isn’t about sound systems, it’s experience monetization at scale.
Aqua Metals Inc. (NASDAQ:AQMS) jumped after announcing a $13 million registered direct offering, priced at $11.34/share with 5-year prefunded warrants.
- Proceeds will go toward working capital and the scaling of AquaRefining, the company’s proprietary lithium battery recycling tech.
As the EV race heats up, AQMS continues to draw institutional interest in its closed-loop, zero-emission approach to critical materials recovery.
Semiconductors remain a focal point, with AI infrastructure and hyperscaler tailwinds continuing to push select names:
- Navitas Semiconductor (NASDAQ:NVTS) is on the move as traders bet on next-gen GaN and SiC chips amid rising data center efficiency demands.
- Intel Corporation (NASDAQ:INTC) continues its fab investment narrative, with eyes on geopolitical tailwinds as U.S. reshoring gets Congressional attention.
- Advanced Micro Devices (NASDAQ:AMD) trades sideways but holds firm above key support, with momentum building ahead of upcoming AI accelerator benchmarks.
- Applied Digital Corporation (NASDAQ:APLD) is still riding the AI compute infrastructure wave, as capital pours into GPU hosting and cloud AI services.
Energous (NASDAQ:WATT) is getting attention today on strong revenue and operational improvement momentum in its wireless power business. The company recently reported preliminary Q3 2025 revenue of ~$1.3 million, marking its highest quarterly revenue since 2015 and a strong sequential gain. Meanwhile, its order backlog is expanding, with commitments from multiple enterprise customers including a Fortune‑10 company. On the corporate structure side, Energous executed a 1-for-30 reverse stock split earlier this year to maintain compliance with Nasdaq minimum bid rules, a move still influencing share liquidity and perception.
Nova Minerals (NASDAQ:NVA) is actively trading amid a wave of structural and strategic announcements. The company has filed a 5-for-1 forward split of its ADS program — changing the underlying ratio to improve liquidity and accessibility. It’s also pursuing a secondary offering (1.2 million ADSs at $9.25 each) to raise funds for exploration, feasibility studies, and working capital for its Estelle Project in Alaska. On top of that, Nova has recently drawn attention for $43.4 million in U.S. Department of Defense funding toward antimony development and secured a land-use permit for a proposed Refinery at Port MacKenzie, Alaska, signaling serious intent to produce “military-grade” critical minerals.
Personalis (NASDAQ:PSNL) continues to trade actively on its advancing diagnostic platform and strategic partnerships. The company recently expanded its agreement with Tempus AI, adding colorectal cancer as a new indication for its NeXT Personal® test and extending exclusivity terms through 2028. This makes its liquid biopsy offering relevant across more cancer types. Separately, Personalis also granted inducement stock options under Nasdaq rules to new management hires, a signal of talent investment and alignment. Previous moves included a workforce reduction (~20%) to reduce costs and extend its cash runway potentially into 2026, in conjunction with its Tempus collaboration.
Grail (NASDAQ:GRAL) is in the spotlight today following a major strategic collaboration and equity investment by Samsung (Samsung C&T & Samsung Electronics). The companies inked a binding Letter of Intent under which Samsung will invest $110 million at $70.05/share and commercialize Grail’s Galleri multi-cancer early-detection test in South Korea, with possible expansion to other Asian markets. Shares jumped ~14–15% on the news in premarket trading.
Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.
For the full 24/7 Market News VENU report and in-depth insights, including analyst reports, visit: Read 24/7 Market News VENU Report/
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated $2,500 per week by MicroCap Strategies for ongoing press and editorial coverage of VENU. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
CONTACT:
24/7 Market News
Editor@247marketnews.com